CLL
Conditions
Brief summary
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Interventions
DRUGBTK inhibitor
patients with treatment naive or R/R CLL who treatment with BTK inhibitor
Sponsors
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients aged ≥18 years old 2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL \[International Workshop on Chronic Lymphocytic Leukemia\] criteria)； 3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor; 4. Prior or current use of BTK inhibitor for ≥3 months 5. At least one follow-up was recorded during BTK inhibitor treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | up to five years | OS is defined as the time from the starting date of BTK inhibitor to the date of death due to any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Next Therapy (TTNT) | up to two years | The TTNT will be calculated as the difference between BTK inhibitor initiation date and initiation date of the first next therapy for CLL |
| Adverse Events | up to five years | Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Special Situations |
Contacts
Primary ContactShengmiao Yang, MD
Outcome results
None listed